Avantor, Inc. (NYSE:AVTR) Shares Acquired by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. lifted its stake in shares of Avantor, Inc. (NYSE:AVTR) by 16.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 47,732 shares of the company’s stock after purchasing an additional 6,668 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Avantor were worth $1,235,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the stock. Versant Capital Management Inc boosted its holdings in Avantor by 2,003.6% in the 2nd quarter. Versant Capital Management Inc now owns 1,157 shares of the company’s stock valued at $25,000 after purchasing an additional 1,102 shares in the last quarter. Blue Trust Inc. lifted its holdings in shares of Avantor by 1,830.3% in the 2nd quarter. Blue Trust Inc. now owns 1,467 shares of the company’s stock valued at $31,000 after buying an additional 1,391 shares during the period. UMB Bank n.a. purchased a new stake in shares of Avantor in the third quarter valued at approximately $49,000. Nisa Investment Advisors LLC grew its holdings in Avantor by 69.6% during the third quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company’s stock worth $53,000 after acquiring an additional 835 shares during the period. Finally, GAMMA Investing LLC grew its holdings in Avantor by 89.9% during the third quarter. GAMMA Investing LLC now owns 2,715 shares of the company’s stock worth $70,000 after acquiring an additional 1,285 shares during the period. 95.08% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have commented on AVTR. Robert W. Baird decreased their target price on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a research report on Monday, October 28th. Royal Bank of Canada reissued an “outperform” rating and set a $34.00 price objective on shares of Avantor in a report on Thursday, September 26th. Wells Fargo & Company dropped their target price on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a report on Monday, October 28th. Barclays decreased their price target on Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a research note on Friday, October 25th. Finally, UBS Group dropped their price objective on Avantor from $30.00 to $29.00 and set a “buy” rating for the company in a research note on Tuesday, October 8th. Three analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $27.57.

Avantor Price Performance

Avantor stock opened at $21.04 on Thursday. The firm has a fifty day moving average of $23.53 and a 200-day moving average of $23.78. Avantor, Inc. has a 52-week low of $19.59 and a 52-week high of $28.00. The company has a quick ratio of 1.06, a current ratio of 1.54 and a debt-to-equity ratio of 0.84. The firm has a market capitalization of $14.32 billion, a P/E ratio of 45.74, a PEG ratio of 2.56 and a beta of 1.35.

Insider Buying and Selling

In other news, CAO Steven W. Eck sold 3,525 shares of the business’s stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $25.06, for a total transaction of $88,336.50. Following the transaction, the chief accounting officer now directly owns 29,544 shares of the company’s stock, valued at approximately $740,372.64. The trade was a 10.66 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.30% of the stock is owned by corporate insiders.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.